DMC's Green Light
Analyst David Lebowitz pointed out that Alnylam had directed its DMC to conduct an interim assessment of the Phase 3 APOLLO trial for patisiran for the treatment of hereditary amyloidosis with polyneuropathy to evaluate for safely. This follows a DMC recommendation that the phase 3 ENDEAVOUR trial be discontinued due to an imbalance of deaths between the experimental and control arms.
On Track For Mid-2017 Data Presentation
Morgan Stanley noted that the management is confident of a mid-2017 date for data presentation from this Phase III trial. The DMC is expected to meet periodically to evaluate the safety of the drug through the trial's conclusion, the firm said.
Shares To Be Range Bound
The firm sees the company's shares to be range bound in the coming months, given challenges with revusiran, the discontinuation of ALN-AAT due to elevated liver enzymes as well as other AEs. Some of the questions concerning revusiran for which investors would seek answers are whether the challenges associated with it are drug-specific, TTR-mechanism specific or platform specific.
Morgan Stanley has an Equal-Weight rating on the shares of the company and a $36 price target.
At last check, Alnylam shares were up 3.38 percent at $35.41.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.